摘要
背景:由于移植技术的提高,供受者ABO血型不合已不再是异基因造血干细胞移植的障碍,但是由于宿主血凝素抗体的持续存在,ABO血型不合异基因造血干细胞移植后常出现红细胞系统恢复的延迟。目的:观察ABO血型不合异基因造血干细胞移植患者红细胞系统恢复情况,评价血型不合、人类白细胞抗原配型不相合对造血功能重建的影响。设计:回顾性分析。单位:南京大学医学院附属鼓楼医院血液科。对象:选择2002-05/2007-09在南京大学医学院附属鼓楼医院血液科行ABO血型不合异基因造血干细胞移植的恶性血液患者(受者)14例,男11例,女3例;年龄15~60岁。14例患者中7例供受者人类白细胞抗原配型完全相合,7例供受者人类白细胞抗原配型半相合。纳入同期ABO血型相合的造血干细胞移植患者11例为对照。受者在接受异基因造血干细胞移植前签署移植同意书,供者为同胞姊妹、胞弟、儿子、母亲,均同意提供用于移植的骨髓。实验经医院伦理委员会批准。方法:①预处理方案:人类白细胞抗原配型全相合组采取马利兰和环磷酰胺为主的方案。人类白细胞抗原配型半不合组采用北京人民医院的GIAC方案。②造血干细胞输注:沉降供者骨髓,取上层有核细胞输给受者。主要观察指标:观察ABO血型不合异基因造血干细胞移植的副反应、并发症及造血重建情况。结果:14例ABO血型不合患者仅1例发生单纯红细胞再生障碍性贫血未进入结果分析。①造血功能重建情况:与对照组比较,ABO血型不合组血红蛋白恢复时间明显延迟(t=2.352,P〈0.05),ABO血型相同与ABO血型不合组中性粒细胞和血小板恢复情况差异无显著性意义(P〉0.05)。ABO血型不合的人类白细胞抗原配型半不合造血干细胞组血红蛋白恢复和血型转换时间迟于全相合,但其差异无显著性意义(P〉0.05)。②并发症:14例ABO血型不合患者移植后成分输血过程未出现溶血反应,移植后也均未发生迟发性溶血反应。结论:ABO血型不合不影响造血干细胞移植的效果,且较为安全。
BACKGROUND: ABO-incompatibility between donor and recipient is not a barrier for successful allogeneic hematopoietic stem cell transplantation even though it is well established that major ABO incompatibility may lead to prolonged destruction of donor-derived erythrocytes and prolonged transfusion requirements. OBJECTIVE: To explore the effect of ABO-incompatible on clinical characteristics in allogeneic-hematopoietic stem cell transplantation. DESIGN: A retrospective observation. SETTING: Department of Hematology, the Affiliated Drum Tower Hospital of Nanjing University Medical School. PARTICIPANTS: Fourteen patients (11 males and 3 females, aged 15-60 years old) with malignant hematologic diseases who received ABO-incompatible allogeneic hematopoietic stem cell transplantation in the Affiliated Drum Tower Hospital of Nanjing University Medical School from May 2002 to September 2007 were recruited for this study. Of the 14 patients, 7 were human leukocyte antigen (HLA)-matched, and the other 7 were HLA-half-matched. Controls were 11 patients who received ABO-compatibility bone marrow transplantation during the same period. Written informed consents for receiving allogeneic hematopoietic stem cell transplantation were obtained from each recipient. The donors were sibling sister, sibling brother, son and mother, and they all agreed to provide marrow for transplantation. This experiment was given an approval by the Ethics Committees of the hospital. METHODS: Regimen conditioning: HLA-matched transplantation regimen conditioning consisted of busulfan (Bu) and cyclophosphamide (Cy). HLA-half-matched transplantation regimen conditioning adopted GIAC program from Beijing People's Hospital. The GIAC program consisted of 4 parts: G: granulocyte colony-stimulating factors used for donors; I: stronger immunosuppressive regimen conditioning used for recipients; A: antihuman thymocyte globulin added; C: combined transplantation of bone marrow and peripheral blood; Perfusion of hematopoietic stem cells: The marrow from ABO- incompatible donor depleted erythrocytes by hydroxyethyl starch sedimentation. MAIN OUTCOME MEASURES: Adverse reaction, complication and hematologic recovery after ABO-incompatibility stem cell transplantation. RESULTS: One out of fourteen recipients developed pure red cell aplasia (PRCA) and dropped out of final analysis. Hematologic recovery: The median time of erythrocyte recovery after ABO-incompatible stem cell transplantation was delayed compared with ABO compatible stem cell transplantation (t=-2.352, P 〈 0.05). There were no significant differences in the recovery of neutrophils and platelets between ABO-incompatible group and ABO-compatible group (P 〉 0.05). The median time of recovery of the erythrocyte and the blood type switching was delayed in HLA-mis-matched allogeneic hematopoietic stem cell transplantation compared with HLA-matched allogeneic hematopoietic stem cell transplantation, but without significant difference (P 〉 0.05). Complications: During the stem cell transfusion following transplantation, none of 14 patients had hemolytic complications or delayed haemolysis. CONCLUSION: There was no evidence of ABO-incompatibility between donor and recipient is a barrier for successful allogeneic hematopoietic stem cell transplantation.
出处
《中国组织工程研究与临床康复》
CAS
CSCD
北大核心
2008年第12期2383-2386,共4页
Journal of Clinical Rehabilitative Tissue Engineering Research
基金
the Project of Jiangsu Provincial Society Development,No.BS2004008